Articles
The Jefferson School of Pharmacy at Thomas Jefferson University was founded in 2008 and offers an innovative doctor of pharmacy program that prepares graduates for interesting and challenging pharmacy practice roles across the healthcare continuum. Read More ›
The Jefferson School of Pharmacy at Thomas Jefferson University was founded in 2008 and offers an innovative doctor of pharmacy program that prepares graduates for interesting and challenging pharmacy practice roles across the healthcare continuum. Read More ›
The Jefferson School of Pharmacy at Thomas Jefferson University was founded in 2008 and offers an innovative doctor of pharmacy program that prepares graduates for interesting and challenging pharmacy practice roles across the healthcare continuum. Read More ›
The Jefferson School of Pharmacy at Thomas Jefferson University was founded in 2008 and offers an innovative doctor of pharmacy program that prepares graduates for interesting and challenging pharmacy practice roles across the healthcare continuum. Read More ›
The Jefferson School of Pharmacy at Thomas Jefferson University was founded in 2008 and offers an innovative doctor of pharmacy program that prepares graduates for interesting and challenging pharmacy practice roles across the healthcare continuum. Read More ›
Multiple Myeloma Research Foundation Live Event: Precision Medicine and Big Data in Multiple Myeloma
In this continuing education activity, frequently asked questions gathered from the community will be addressed to myeloma experts. Read More ›
Multiple Myeloma Research Foundation Live Event: Precision Medicine and Big Data in Multiple Myeloma
In this continuing education activity, frequently asked questions gathered from the community will be addressed to myeloma experts. Read More ›
Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business. Read More ›
The Cancer Genome Atlas (TCGA) project now includes a recently reported comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma. Read More ›
Immunotherapy with ipilimumab improved progression-free survival (PFS) and prostate-specific antigen response compared with placebo, but improvement in overall survival (OS) failed to reach statistical significance in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). These results of a randomized phase 3 trial (CA184-043) were presented at the 2014 Genitourinary Cancers Symposium. Read More ›